InvestorsHub Logo
Followers 40
Posts 6081
Boards Moderated 1
Alias Born 06/29/2011

Re: Lunacy_John Galt post# 9572

Tuesday, 11/26/2019 12:30:01 AM

Tuesday, November 26, 2019 12:30:01 AM

Post# of 17590
Luna, your last paragraph is why I think they are so enthused with the P3 design. Why would they use an enrollment design that will tip the scale against the drug. CoolG said it is a requirement by the FDA, that the race percentage makeup of the P2 trial will not pass approval fromFDA..
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News